Published in J Transl Med on December 18, 2008
Dendrimer-based postnatal therapy for neuroinflammation and cerebral palsy in a rabbit model. Sci Transl Med (2012) 3.43
Toxicity and cellular uptake of gold nanoparticles: what we have learned so far? J Nanopart Res (2010) 2.70
Multimodality imaging probes: design and challenges. Chem Rev (2010) 2.61
Specific targeting of brain tumors with an optical/magnetic resonance imaging nanoprobe across the blood-brain barrier. Cancer Res (2009) 2.28
Physiologic upper limits of pore size of different blood capillary types and another perspective on the dual pore theory of microvascular permeability. J Angiogenes Res (2010) 2.11
A nanoparticle size series for in vivo fluorescence imaging. Angew Chem Int Ed Engl (2010) 1.84
New strategies to deliver anticancer drugs to brain tumors. Expert Opin Drug Deliv (2009) 1.29
Review of Neurosurgical Fluorescence Imaging Methodologies. IEEE J Sel Top Quantum Electron (2010) 1.29
A review of nanoparticle functionality and toxicity on the central nervous system. J R Soc Interface (2010) 1.21
Tissue concentration of systemically administered antineoplastic agents in human brain tumors. J Neurooncol (2011) 1.14
Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm Res (2010) 1.12
Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med (2009) 1.11
Current approaches to enhance CNS delivery of drugs across the brain barriers. Int J Nanomedicine (2014) 1.02
Noninvasive monitoring of orthotopic glioblastoma therapy response using RGD-conjugated iron oxide nanoparticles. Biomaterials (2012) 1.02
Nanoparticles for brain drug delivery. ISRN Biochem (2013) 0.99
A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma. Nanomedicine (Lond) (2012) 0.97
Recent progress towards development of effective systemic chemotherapy for the treatment of malignant brain tumors. J Transl Med (2009) 0.95
Determining molecular mass distributions and compositions of functionalized dendrimer nanoparticles. Nanomedicine (Lond) (2009) 0.95
Nanoparticles for imaging and treating brain cancer. Nanomedicine (Lond) (2013) 0.90
Pharmacodynamic analysis of magnetic resonance imaging-monitored focused ultrasound-induced blood-brain barrier opening for drug delivery to brain tumors. Biomed Res Int (2013) 0.90
Which drug or drug delivery system can change clinical practice for brain tumor therapy? Neuro Oncol (2013) 0.88
Hybrid magnetic nanostructures (MNS) for magnetic resonance imaging applications. Adv Drug Deliv Rev (2011) 0.85
Targeted delivery of antibody-based therapeutic and imaging agents to CNS tumors: crossing the blood-brain barrier divide. Expert Opin Drug Deliv (2013) 0.85
Cancer nanotechnology: emerging role of gold nanoconjugates. Anticancer Agents Med Chem (2011) 0.84
Metabolically stable bradykinin B2 receptor agonists enhance transvascular drug delivery into malignant brain tumors by increasing drug half-life. J Transl Med (2009) 0.84
Blood-brain barrier permeable gold nanoparticles: an efficient delivery platform for enhanced malignant glioma therapy and imaging. Small (2014) 0.83
Recent advances in RNA interference therapeutics for CNS diseases. Neurotherapeutics (2013) 0.81
Uniform brain tumor distribution and tumor associated macrophage targeting of systemically administered dendrimers. Biomaterials (2015) 0.81
Peptide-Targeted Gold Nanoparticles for Photodynamic Therapy of Brain Cancer. Part Part Syst Charact (2015) 0.80
Systemic dendrimer-drug treatment of ischemia-induced neonatal white matter injury. J Control Release (2015) 0.80
Targeted Doxorubicin Delivery to Brain Tumors via Minicells: Proof of Principle Using Dogs with Spontaneously Occurring Tumors as a Model. PLoS One (2016) 0.79
Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors. Ther Deliv (2010) 0.78
Nanotechnology Approaches to Targeting Inflammation and Excitotoxicity in a Canine Model of Hypothermic Circulatory Arrest-Induced Brain Injury. Ann Thorac Surg (2016) 0.78
Nanoscale effects in dendrimer-mediated targeting of neuroinflammation. Biomaterials (2016) 0.78
Novel peptide-dendrimer conjugates as drug carriers for targeting nonsmall cell lung cancer. Int J Nanomedicine (2010) 0.78
Nanoparticle-facilitated functional and molecular imaging for the early detection of cancer. Front Mol Biosci (2014) 0.77
Targeting Glioma with a Dual Mode Optical and Paramagnetic Nanoprobe across the Blood-brain Tumor Barrier. J Nanomed Nanotechnol (2016) 0.77
Cellular imaging of endosome entrapped small gold nanoparticles. MethodsX (2015) 0.77
Phosphatidylserine-targeted liposome for enhanced glioma-selective imaging. Oncotarget (2016) 0.75
Generation-6 hydroxyl PAMAM dendrimers improve CNS penetration from intravenous administration in a large animal brain injury model. J Control Release (2017) 0.75
A choline derivate-modified nanoprobe for glioma diagnosis using MRI. Sci Rep (2013) 0.75
Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma. Curr Neuropharmacol (2016) 0.75
Lumbar puncture-administered resveratrol inhibits STAT3 activation, enhancing autophagy and apoptosis in orthotopic rat glioblastomas. Oncotarget (2016) 0.75
Tailored theranostic apolipoprotein E3 porphyrin-lipid nanoparticles target glioblastoma. Chem Sci (2017) 0.75
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med (2005) 74.55
AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput Biomed Res (1996) 53.52
A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Res (1986) 15.83
Estimating kinetic parameters from dynamic contrast-enhanced T(1)-weighted MRI of a diffusable tracer: standardized quantities and symbols. J Magn Reson Imaging (1999) 13.26
Renal clearance of quantum dots. Nat Biotechnol (2007) 12.54
Drug delivery systems: entering the mainstream. Science (2004) 9.27
Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A (1998) 7.78
Drug delivery and targeting. Nature (1998) 6.16
Measurement of the blood-brain barrier permeability and leakage space using dynamic MR imaging. 1. Fundamental concepts. Magn Reson Med (1991) 5.33
Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med (1980) 4.90
Nanoparticle targeting of anticancer drug improves therapeutic response in animal model of human epithelial cancer. Cancer Res (2005) 4.71
A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro Oncol (2003) 4.17
Blood volume in the rat. J Nucl Med (1985) 3.40
Iron oxide nanoparticles as a drug delivery vehicle for MRI monitored magnetic targeting of brain tumors. Biomaterials (2007) 3.12
Dendrimers: relationship between structure and biocompatibility in vitro, and preliminary studies on the biodistribution of 125I-labelled polyamidoamine dendrimers in vivo. J Control Release (2000) 3.07
Monocrystalline iron oxide nanocompounds (MION): physicochemical properties. Magn Reson Med (1993) 3.01
Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, ferumoxtran, ferumoxsil. Magn Reson Imaging (1995) 2.67
Temozolomide: a review of its discovery, chemical properties, pre-clinical development and clinical trials. Cancer Treat Rev (1997) 2.62
Rat brain tumor models in experimental neuro-oncology: the 9L, C6, T9, F98, RG2 (D74), RT-2 and CNS-1 gliomas. J Neurooncol (1998) 2.34
Nano-sized MRI contrast agents with dendrimer cores. Adv Drug Deliv Rev (2005) 2.33
Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. Biochem Soc Trans (2007) 2.19
Strategies to advance translational research into brain barriers. Lancet Neurol (2008) 2.16
Tumoral distribution of long-circulating dextran-coated iron oxide nanoparticles in a rodent model. Radiology (2000) 2.11
Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol (2007) 2.09
Molecular dynamics simulations suggest a mechanism for translocation of the HIV-1 TAT peptide across lipid membranes. Proc Natl Acad Sci U S A (2007) 1.98
Rhodamine 6G. A potent inhibitor of mitochondrial oxidative phosphorylation. J Biol Chem (1974) 1.87
Dendrimer-based metal chelates: a new class of magnetic resonance imaging contrast agents. Magn Reson Med (1994) 1.86
Toxicity and tissue distribution of magnetic nanoparticles in mice. Toxicol Sci (2005) 1.83
Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg (1991) 1.81
Unusual retention of rhodamine 123 by mitochondria in muscle and carcinoma cells. Proc Natl Acad Sci U S A (1982) 1.72
Nanoparticle surface charges alter blood-brain barrier integrity and permeability. J Drug Target (2004) 1.65
Imaging, distribution, and toxicity of superparamagnetic iron oxide magnetic resonance nanoparticles in the rat brain and intracerebral tumor. Neurosurgery (2005) 1.61
Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res (1998) 1.43
Glomerular sieving of three neutral polysaccharides, polyethylene oxide and bikunin in rat. Effects of molecular size and conformation. Acta Physiol (Oxf) (2007) 1.41
Microvessel organization and structure in experimental brain tumors: microvessel populations with distinctive structural and functional properties. Microvasc Res (1999) 1.38
Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy. J Neurosurg (1995) 1.36
Therapeutic and diagnostic applications of dendrimers for cancer treatment. Adv Drug Deliv Rev (2008) 1.35
Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol Cancer Ther (2006) 1.33
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
Chemotherapy of brain tumors. Arch Neurol (1977) 1.29
Food and Drug Administration Drug approval summary: temozolomide plus radiation therapy for the treatment of newly diagnosed glioblastoma multiforme. Clin Cancer Res (2005) 1.28
Microvascular abnormalities in virally-induced canine brain tumors. Structural bases for altered blood-brain barrier function. J Neurol Sci (1972) 1.22
Relationship of effective molecular size to systemic clearance in rats of recombinant interleukin-2 chemically modified with water-soluble polymers. J Biol Chem (1988) 1.22
Toward improved syntheses of dendrimer-based magnetic resonance imaging contrast agents: new bifunctional diethylenetriaminepentaacetic acid ligands and nonaqueous conjugation chemistry. J Med Chem (2007) 1.12
Technology Insight: novel imaging of molecular targets is an emerging area crucial to the development of targeted drugs. Nat Clin Pract Oncol (2008) 1.08
Fluorescent dyes modify properties of proteins used in microvascular research. Microcirculation (2003) 1.07
Peptide-derivatized biodegradable nanoparticles able to cross the blood-brain barrier. J Control Release (2005) 1.03
Cell penetrating peptides: how do they do it? J Biol Phys (2008) 1.01
Local treatment of malignant brain tumors using implantable chemotherapeutic polymers. J Natl Compr Canc Netw (2005) 1.01
Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin. Cancer (2001) 1.00
Biological and optical properties of fluorescent nanoparticles developed for intravascular imaging. Microsc Res Tech (2007) 0.99
The RG2 rat glioma model. J Neurooncol (1995) 0.98
Negative preclinical results with stealth nanospheres-encapsulated Doxorubicin in an orthotopic murine brain tumor model. J Control Release (2004) 0.98
Preclinical antitumor efficacy evaluation of dendrimer-based methotrexate conjugates. Anticancer Drugs (2008) 0.97
Quantitative STEM mass measurement of biological macromolecules in a 300 kV TEM. J Microsc (2007) 0.96
The acute intravenous toxicity of biological stains, dyes, and other fluorescent substances. Toxicol Appl Pharmacol (1978) 0.96
Polyamine modification increases the permeability of proteins at the blood-nerve and blood-brain barriers. J Neurochem (1996) 0.95
Polymers to treat brain tumours. Biomaterials (1990) 0.93
Carmustine wafers: localized delivery of chemotherapeutic agents in CNS malignancies. Expert Rev Anticancer Ther (2008) 0.91
Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin. Pharm Res (1994) 0.87
Long-term survival in a rodent brain tumor model by bradykinin-enhanced intra-arterial delivery of a therapeutic herpes simplex virus vector. Cancer Gene Ther (1998) 0.79
A structural model for Alzheimer's beta -amyloid fibrils based on experimental constraints from solid state NMR. Proc Natl Acad Sci U S A (2002) 9.55
Self-propagating, molecular-level polymorphism in Alzheimer's beta-amyloid fibrils. Science (2005) 8.86
An abundance of rare functional variants in 202 drug target genes sequenced in 14,002 people. Science (2012) 7.94
Molecular structural basis for polymorphism in Alzheimer's beta-amyloid fibrils. Proc Natl Acad Sci U S A (2008) 4.84
Pyruvate kinase M2 activators promote tetramer formation and suppress tumorigenesis. Nat Chem Biol (2012) 3.40
Protein oxidation implicated as the primary determinant of bacterial radioresistance. PLoS Biol (2007) 3.22
Scale to predict survival after surgery for recurrent glioblastoma multiforme. J Clin Oncol (2010) 2.67
Regulation of AMPA receptor extrasynaptic insertion by 4.1N, phosphorylation and palmitoylation. Nat Neurosci (2009) 2.47
Targeted killing of cancer cells in vivo and in vitro with EGF-directed carbon nanotube-based drug delivery. ACS Nano (2009) 2.39
Supramolecular structural constraints on Alzheimer's beta-amyloid fibrils from electron microscopy and solid-state nuclear magnetic resonance. Biochemistry (2002) 2.37
Layer-specific variation of iron content in cerebral cortex as a source of MRI contrast. Proc Natl Acad Sci U S A (2010) 2.33
Sex-specific fitness effects of nutrient intake on reproduction and lifespan. Curr Biol (2008) 2.32
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes. Pharmacol Rev (2012) 2.31
Genetic ablation of V2a ipsilateral interneurons disrupts left-right locomotor coordination in mammalian spinal cord. Neuron (2008) 2.28
Efficacy and safety of dutasteride in patients with spinal and bulbar muscular atrophy: a randomised placebo-controlled trial. Lancet Neurol (2011) 2.27
Seeded growth of beta-amyloid fibrils from Alzheimer's brain-derived fibrils produces a distinct fibril structure. Proc Natl Acad Sci U S A (2009) 2.15
Organization of the core structure of the postsynaptic density. Proc Natl Acad Sci U S A (2008) 2.06
Macrophage ABCA1 reduces MyD88-dependent Toll-like receptor trafficking to lipid rafts by reduction of lipid raft cholesterol. J Lipid Res (2010) 1.82
Reciprocal alterations in pre- and postsynaptic inhibitory markers at chandelier cell inputs to pyramidal neurons in schizophrenia. Cereb Cortex (2002) 1.77
Clinical features of spinal and bulbar muscular atrophy. Brain (2009) 1.75
Protein SUMOylation is massively increased in hibernation torpor and is critical for the cytoprotection provided by ischemic preconditioning and hypothermia in SHSY5Y cells. J Cereb Blood Flow Metab (2006) 1.75
Oligomeric structure of the human immunodeficiency virus type 1 envelope protein on the virion surface. J Virol (2002) 1.69
Mass of the postsynaptic density and enumeration of three key molecules. Proc Natl Acad Sci U S A (2005) 1.67
In mice lacking V2a interneurons, gait depends on speed of locomotion. J Neurosci (2009) 1.60
Reduced pyramidal cell somal volume in auditory association cortex of subjects with schizophrenia. Neuropsychopharmacology (2002) 1.55
Collateral sensitivity as a strategy against cancer multidrug resistance. Drug Resist Updat (2012) 1.53
Notch and MAML signaling drives Scl-dependent interneuron diversity in the spinal cord. Neuron (2007) 1.52
Phenotype of V2-derived interneurons and their relationship to the axon guidance molecule EphA4 in the developing mouse spinal cord. Eur J Neurosci (2007) 1.52
The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2). ACS Chem Neurosci (2010) 1.46
SUMOylation participates in induction of ischemic tolerance. J Neurochem (2009) 1.38
Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. Neoplasia (2007) 1.33
PSD-95 is required to sustain the molecular organization of the postsynaptic density. J Neurosci (2011) 1.33
Negative diffusion-weighted imaging after intravenous tissue-type plasminogen activator is rare and unlikely to indicate averted infarction. Stroke (2013) 1.33
Nanoscale 3D cellular imaging by axial scanning transmission electron tomography. Nat Methods (2009) 1.32
Mitochondrial NADH fluorescence is enhanced by complex I binding. Biochemistry (2008) 1.30
Elevated global SUMOylation in Ubc9 transgenic mice protects their brains against focal cerebral ischemic damage. PLoS One (2011) 1.28
Electrophysiological characterization of V2a interneurons and their locomotor-related activity in the neonatal mouse spinal cord. J Neurosci (2010) 1.24
Chimeric ferritin nanocages for multiple function loading and multimodal imaging. Nano Lett (2011) 1.24
Restricted expression of mutant SOD1 in spinal motor neurons and interneurons induces motor neuron pathology. Neurobiol Dis (2007) 1.23
A dual-fluorescence high-throughput cell line system for probing multidrug resistance. Assay Drug Dev Technol (2009) 1.22
Lowering industry firewalls: pre-competitive informatics initiatives in drug discovery. Nat Rev Drug Discov (2009) 1.22
Anti-CD74 antibody-doxorubicin conjugate, IMMU-110, in a human multiple myeloma xenograft and in monkeys. Clin Cancer Res (2005) 1.22
Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther (2008) 1.19
Melanosomal sequestration of cytotoxic drugs contributes to the intractability of malignant melanomas. Proc Natl Acad Sci U S A (2006) 1.18
Manganese transport and trafficking: lessons learned from Saccharomyces cerevisiae. Eukaryot Cell (2005) 1.18
The effect of mutant SOD1 dismutase activity on non-cell autonomous degeneration in familial amyotrophic lateral sclerosis. Neurobiol Dis (2009) 1.15
Evidence for dual mode of action of a thiosemicarbazone, NSC73306: a potent substrate of the multidrug resistance linked ABCG2 transporter. Mol Cancer Ther (2007) 1.13
Optimizing bispecific antibody pretargeting for use in radioimmunotherapy. Clin Cancer Res (2003) 1.12
Cisplatin sensitivity mediated by WEE1 and CHK1 is mediated by miR-155 and the miR-15 family. Cancer Res (2012) 1.11
Physiologic upper limit of pore size in the blood-tumor barrier of malignant solid tumors. J Transl Med (2009) 1.11
Preclinical therapy of breast cancer with a radioiodinated humanized anti-EGP-1 monoclonal antibody: advantage of a residualizing iodine radiolabel. Breast Cancer Res Treat (2004) 1.10
Dedifferentiation of adult human myoblasts induced by ciliary neurotrophic factor in vitro. Mol Biol Cell (2005) 1.09
Molecular mechanisms of attenuation of the Sabin strain of poliovirus type 3. J Virol (2004) 1.08
The transcription factor Erg regulates expression of histone deacetylase 6 and multiple pathways involved in endothelial cell migration and angiogenesis. Blood (2011) 1.07
Brain redox imaging using blood-brain barrier-permeable nitroxide MRI contrast agent. J Cereb Blood Flow Metab (2008) 1.06
Frequency-dependent recruitment of V2a interneurons during fictive locomotion in the mouse spinal cord. Nat Commun (2011) 1.05
Identification of compounds selectively killing multidrug-resistant cancer cells. Cancer Res (2009) 1.05
A universal pretargeting system for cancer detection and therapy using bispecific antibody. Cancer Res (2003) 1.05
Distribution and clearance of PEG-single-walled carbon nanotube cancer drug delivery vehicles in mice. Nanomedicine (Lond) (2010) 1.04
Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res (2003) 1.03
Lysosomal trapping of a radiolabeled substrate of P-glycoprotein as a mechanism for signal amplification in PET. Proc Natl Acad Sci U S A (2011) 1.03
Antibodies against low-density lipoprotein receptor-related protein 4 induce myasthenia gravis. J Clin Invest (2013) 1.03
Gain-of-function glutamate receptor interacting protein 1 variants alter GluA2 recycling and surface distribution in patients with autism. Proc Natl Acad Sci U S A (2011) 1.03
Promoting trimerization of soluble human immunodeficiency virus type 1 (HIV-1) Env through the use of HIV-1/simian immunodeficiency virus chimeras. J Virol (2004) 1.03
Enhanced MRI relaxivity of Gd(3+) -based contrast agents geometrically confined within porous nanoconstructs. Contrast Media Mol Imaging (2012) 1.02
Functional outcome after resection of spinal cord hemangioblastomas associated with von Hippel-Lindau disease. J Neurosurg Spine (2010) 1.02
Truncated wild-type SOD1 and FALS-linked mutant SOD1 cause neural cell death in the chick embryo spinal cord. Neurobiol Dis (2005) 1.01
Self-assembly of amphiphilic plasmonic micelle-like nanoparticles in selective solvents. J Am Chem Soc (2013) 1.00
Targeting the Achilles heel of multidrug-resistant cancer by exploiting the fitness cost of resistance. Chem Rev (2014) 1.00
Near infrared-fluorescent and magnetic resonance imaging molecular probe with high T1 relaxivity for in vivo multimodal imaging. Chem Commun (Camb) (2010) 0.99
Dyslipidemia induces opposing effects on intrapulmonary and extrapulmonary host defense through divergent TLR response phenotypes. J Immunol (2010) 0.98
N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos (2010) 0.98
68Ga-DOTA-affibody molecule for in vivo assessment of HER2/neu expression with PET. Eur J Nucl Med Mol Imaging (2011) 0.97
Natural history of pulmonary function in collagen VI-related myopathies. Brain (2013) 0.97
Glutamate synapses in human cognitive disorders. Annu Rev Neurosci (2015) 0.96
Quantitative STEM mass measurement of biological macromolecules in a 300 kV TEM. J Microsc (2007) 0.96
Bioluminescent imaging of drug efflux at the blood-brain barrier mediated by the transporter ABCG2. Proc Natl Acad Sci U S A (2013) 0.96
Down-regulation of a manganese transporter in the face of metal toxicity. Mol Biol Cell (2009) 0.96
Apolipoprotein E protects astrocytes from hypoxia and glutamate-induced apoptosis. FEBS Lett (2012) 0.95
Development of a MR-visible compound for tracing neuroanatomical connections in vivo. Neuron (2011) 0.95
Identification of BLyS (B lymphocyte stimulator), a non-myelin-associated protein, as a functional ligand for Nogo-66 receptor. J Neurosci (2009) 0.94
2-Oxo-N-aryl-1,2,3,4-tetrahydroquinoline-6-sulfonamides as activators of the tumor cell specific M2 isoform of pyruvate kinase. Bioorg Med Chem Lett (2011) 0.94
Minipig and beagle animal model genomes aid species selection in pharmaceutical discovery and development. Toxicol Appl Pharmacol (2013) 0.94
Sex differences in nutrient-dependent reproductive ageing. Aging Cell (2009) 0.94
Effects of interleukin-6, leukemia inhibitory factor, and ciliary neurotrophic factor on the proliferation and differentiation of adult human myoblasts. Cell Mol Neurobiol (2008) 0.93
Dual-axis electron tomography of biological specimens: Extending the limits of specimen thickness with bright-field STEM imaging. J Struct Biol (2010) 0.92